Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Drug Interaction Study of D326, D337, and D013 (CKD-386) in Healthy Males
NCT03609606Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Aug 2018
- Primary completion
- Sep 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of telmisartan, rosuvastatin and ezetimibe in hypertension (HTN) and dyslipidemia (4 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area under the plasma concentration-time curve for a dosing interval at steady state at Day 28 and Maximum plasma concentration of the drug at steady state at Day 28. Started Aug 2018; status: completed.
02
Drugs
telmisartanrosuvastatinezetimibe
03
Conditions
hypertension (HTN)dyslipidemia
Beyond the preview
Go deeper on NCT03609606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03609606.